Literature DB >> 3111761

Immunological studies on Kawasaki disease: II. Isolation and characterization of an immunosuppressive factor in acute phase sera.

J Hirao, N Yoshimura, N Homma, K Kano.   

Abstract

Acute phase serum from a patient with Kawasaki disease possessed strong inhibitory activity for the proliferative response of Con A-stimulated peripheral blood mononuclear cells. The inhibitor was fractionated step-wise by means of DEAE-Sephadex A-50 ion exchange chromatography followed by Sephadex G-100 gel filtration and high performance liquid chromatography. A major protein of 140 kD with 2000 times greater inhibitory activity than the original serum was identified in the final fraction. Immunization of mice with this fraction resulted in the production of three hybridoma clones secreting monoclonal antibodies (MoAb) of IgG1 class which blocked the inhibitory activity of the fraction. Two of these MoAb recognized the same epitope of the inhibitory factor, while the remaining MoAb was directed to a different epitope. Western blot analysis of acute phase sera by the MoAb demonstrated the presence of 140 kD molecules in 43 of 55 patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111761      PMCID: PMC1542606     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Mucocutaneous lymph node syndrome (MLNS) in the continental United States.

Authors:  R W Goldsmith; D Gribetz; L Strauss
Journal:  Pediatrics       Date:  1976-03       Impact factor: 7.124

2.  Elevated levels of immunoglobulin E in the acute febrile mucocutaneous lymph node syndrome.

Authors:  S Kusakawa; D C Heiner
Journal:  Pediatr Res       Date:  1976-02       Impact factor: 3.756

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

6.  Hanganutziu-Deicher antibodies in infectious mononucleosis and other diseases.

Authors:  T Morito; K Kano; F Milgrom
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Immunoregulatory T cell abnormalities in mucocutaneous lymph node syndrome.

Authors:  D Y Leung; E T Chu; N Wood; S Grady; R Meade; R S Geha
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

8.  Distinction of epitopes by monoclonal antibodies.

Authors:  C Stähli; V Miggiano; J Stocker; T Staehelin; P Häring; B Takács
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

9.  The use of the avidin-biotin complex as a tool in molecular biology.

Authors:  E A Bayer; M Wilchek
Journal:  Methods Biochem Anal       Date:  1980

10.  Immunological studies on Kawasaki disease. I. Appearance of Hanganutziu-Deicher antibodies.

Authors:  M Takiguchi; T Tamura; M Goto; S Kusakawa; F Milgrom; K Kano
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

  10 in total
  2 in total

1.  Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease.

Authors:  J C Burns; C Shimizu; H Shike; J W Newburger; R P Sundel; A L Baker; T Matsubara; Y Ishikawa; V A Brophy; S Cheng; M A Grow; L L Steiner; N Kono; R M Cantor
Journal:  Genes Immun       Date:  2005-08       Impact factor: 2.676

2.  A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Authors:  Wei Li; Xiufang He; Li Zhang; Zhouping Wang; Yanfei Wang; Huimei Lin; Jia Yuan; Xiaofei Xie; Youzhen Qin; Ping Huang
Journal:  Cardiovasc Ther       Date:  2021-06-18       Impact factor: 3.023

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.